Why the synergy between biotech companies and PLG makes sense

Why the synergy between biotech companies and PLG makes sense

Discovering and developing breakthrough new medical treatments that alleviate suffering, extend life, and improve quality of life require time, great people, significant resources, collaboration across sectors and geographic borders, and complex and risky processes—with no guarantee of success.

From conception and development to approval and launch, each stage of the commercialization process requires individuals with various kinds of specific expertise in areas ranging from clinical data collection to capturing and reporting adverse events. Today’s ever-changing laws and regulations have led to a growing demand for professionals who understand the overall regulatory landscape and can help companies effectively bring products to market. Developing that understanding requires staying up-to-date on emerging trends within the industry.

PLG has assembled a team of biopharmaceutical regulatory experts who have extensive experience in and deep understanding of the areas of biopharmaceutical product development, registration, market access, health economics, and commercialization.

PLG provides flexible and tailored, preclinical, clinical, and market access solutions designed to help small and midsize biopharmaceutical companies move forward in their efforts to get treatments to patients—from helping define a development plan to assisting with the implementation of all stages of product development and through launch and commercialization—in order to deliver compelling results to regulatory authorities, investors, and stakeholders.

PLG assists companies in reaching their product development milestones faster and in effectively managing their development programs from preclinical to postmarketing stages.

Read more about our flexible and tailored, early-stage, preclinical, clinical, and market access solutions.

The ability of biopharmaceutical products to address previously untreatable diseases is leading to unprecedented acceptance of innovative treatments.

Ahmed Bouzidi

Vice President, Biotech Strategic Development

Ahmed Bouzidi